BIOLASE Wins FDA Clearance for 940nm Diolase 10 Diode Soft Tissue Laser

BIOLASE, Inc. (NASDAQ: BIOL), the world's leading manufacturer and distributor of dentallasers, announced today that the U.S. Food and Drug Administration(FDA) has cleared the 940nm Diolase 10 diode soft tissue laser foruse in 19 additional medical markets including: ear, nose and throat,oral surgery, arthroscopy, gastroenterology, general surgery,dermatology, plastic surgery, podiatry, GI/GU, gynecology,neurosurgery, ophthalmology, pulmonary surgery, cardiac surgery,thoracic surgery, urology, dermatology, aesthetics, and vascularsurgery. This FDA clearance includes over 80 different procedures. BIOLASE's diode lasers are used in dentistry for surgical soft tissueprocedures as an alternative to invasive and traumatic conventionaldevices, such as the high-speed drill, scalpel or electrosurge. The940nm wavelength is better absorbed by hemoglobin (Hb) andoxyhemoglobin (HbO2) than other diode laser wavelengths(1), so itcuts efficiently at low power and with considerably less heat anddiscomfort, making it an excellent alternative to conventional surgical devices. BIOLASE's 940nm wavelength is also FDA cleared fortooth whitening and temporary pain relief in a number of BIOLASEproducts.